Erica Clark
Primary Care · Citrus Springs, FLNPI 1023510708
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 491 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 48 manufacturers, the largest accounting for just 15.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $3,085 and has fallen 51.1% since, to $1,509 in 2025. Among primary care clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 491 payments — averaging $21.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Novo Nordisk$1K
- AstraZeneca$1K
- Pfizer$1K
- GSK$939
- Biohaven Pharmaceuticals, Inc.$533
- plus $4K from 42 others
What the payments were for
- Food & beverage$10,50399%
- Education$1001%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,603 in reported general payments places this provider in the 95th percentile of 725 primary care providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 81 | $122,423 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 101 | $103,233 |
| MounjaroTirzepatide | 56 | $65,905 |
| FarxigaDapagliflozin Propanediol | 37 | $52,228 |
| EliquisApixaban | 36 | $43,680 |
| RexultiBrexpiprazole | 26 | $43,051 |
| RybelsusSemaglutide | 14 | $33,309 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 39 | $32,845 |
| TrulicityDulaglutide | 18 | $30,810 |
| XareltoRivaroxaban | 22 | $28,546 |
| MyrbetriqMirabegron | 32 | $22,943 |
| JardianceEmpagliflozin | 17 | $19,125 |
| VascepaIcosapent Ethyl | 17 | $14,822 |
| JanuviaSitagliptin Phosphate | 13 | $13,638 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 15 | $11,935 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,327 | $155,73295 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $939 | $115,168116 claims |
| Lilly USA, LLCMounjaro, Trulicity, Olanzapine | $345 | $102,50786 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $1,155 | $92,29091 claims |
| PfizerEliquis, Premarin | $1,038 | $47,69050 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $381 | $43,05126 claims |
| Johnson & JohnsonXarelto | $343 | $28,54622 claims |
| Astellas Pharma US IncMyrbetriq | $287 | $22,94332 claims |
| Boehringer IngelheimJardiance | $81 | $19,12517 claims |
| MerckJanuvia | $24 | $13,63813 claims |
| AbbVieSynthroid | $1,645 | $2,24636 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 725 primary care providers in Florida.
Other primary care in Citrus Springs
- Paul ChanOrlando$447K
- Jenny WestPensacola$80K
- Railet RodriguezAltamonte Springs$14K
- Kevin HanawayFort Lauderdale$12K
- Kelly ChewningAlachua$11K
- Yolanda PalmeroSaint Cloud$11K
- Michelle SelvaggiLakewood Ranch$10K
- Kristen DeasonTallahassee$10K
- Robert PerriPalm Coast$10K
- Jenna MinniJupiter$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.